Objective: Osteoporosis has become an important public health problem in China, especially among elderly postmenopausal women. Massive amounts of medical and health resources have been devoted to patients with osteoporosis and osteoporosis-related fractures. This study estimated the cost-effectiveness of alendronate, zoledronate, raloxifene, teriparatide, and calcium/vitamin D as treatments for osteoporosis in elderly postmenopausal women in China from the medical system perspective.
O steoporosis has become an important public health problem in China as the country's population continues to age. A previous epidemiological survey has shown that the prevalence rates of osteoporosis among Chinese men and women over 50 years of age are 20.7% and 14.4%, respectively. The prevalence of osteoporosis increases drastically among people over 60 years old, especially among women. 1 Chinese women are more prone to osteoporotic fractures than other populations. Approximately two-fifths of Chinese women aged 50 years old will experience osteoporotic fractures in their remaining life, whereas the worldwide average for these injuries is one-third. 2 Osteoporotic fractures are harmful and are one of the main causes of disability and death among elderly patients. More than 20% of patients die within the first year after a hip fracture because of complications, and approximately 50% of patients become disabled; disability remarkably decreases the quality of life of these patients. 3 The medical treatment and care of osteoporosis and fractures impose a heavy familial and societal burden given their requirement for a considerable amount of manpower and material and financial resources. A forecast in 2015 showed that the medical expenses for major osteoporotic fractures (wrist, vertebral, and hip) in China will reach as high as $19.92 billion and $25.43 billion in 2035 and 2050, respectively. 2 Effective drug therapy can help maintain the quality of life for people with osteoporosis by reducing the risk of osteoporosis-related fractures. Current approaches for the prevention and treatment of osteoporosis include the application of fundamental supplement for bone health and pharmacologic therapies. The fundamental supplement for bone health mainly comprises calcium and vitamin D. The pharmacologic therapies include antiresorptives and bone formation-stimulating regimens, such as diphosphonate, calcitonin, selective estrogen receptor modulators, estrogens, and parathyroid hormone analogs. Alendronate, zoledronate, raloxifene, and teriparatide reduce the risk of fragility fractures and are widely used in Chinese clinical practice. 3 At present, the prevention of osteoporosis and osteoporosisrelated fractures in China is expensive, given the high costs of antiosteoporosis drugs in the country. Given that China is a developing country with a large population and limited medical resources, Chinese policymakers must identify cost-effective drugs for the treatment of osteoporosis in elderly postmenopausal women. Therefore, in this study, we aimed to evaluate the cost-effectiveness of alendronate, zoledronate, raloxifene, teriparatide, and calcium/vitamin D in the treatment of osteoporosis in postmenopausal women in China.
METHODS

Model design
We revised a published Markov state-transition model 4 and conducted a cost-effectiveness analysis of five treatment strategies for postmenopausal women with osteoporosis in China at different initial treatment ages (60, 65, 70, 75, 80, 85, 90, and greater than 90 years) from the medical system perspective ( Fig. 1) . Each cycle comprised 1 year, and the timeframe was 40 years. The model consisted of the following six health states: no fracture; hip fracture; posthip fracture; clinical vertebral fracture; postclinical vertebral fracture; and death. Our model only considered two states of fragility fractures (hip and clinical vertebral fractures) because of the lack of reliable epidemiological data on other osteoporotic fractures in the Chinese setting. The model initially assumed that patients were in a ''no fracture'' state that may persist for years or may enter other health states on the basis of transition probabilities. Patients who have experienced hip fractures (or clinical vertebral fractures) transition to a ''hip fracture'' (or ''clinical vertebral fracture'') state for one cycle and then to the ''posthip fracture'' (or ''postclinical vertebral fracture'' state) or ''death'' state on the basis of transition probabilities. A patient may persist in the ''posthip fracture'' (or ''postclinical vertebral fracture'') state, re-experience hip or clinical vertebral fracture, or die as a result of all-cause. Patients can experience only one fracture per cycle and can experience up to two hip fractures and an unlimited number of clinical vertebral fractures over the entirety of the study period. Quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) were the primary health outcomes used in this study. A discount rate of 3% was applied in cost and QALY calculation. 5 ICER was calculated as follows:
The cost-effectiveness threshold in this study was set as three times the per capita gross domestic product of China in 2017 ($28,624) in accordance with WHO recommendations. [6] [7] [8] TreeAge 2015 (TreeAge Software Inc., Williamstown, MA) was used to program and analyze the model.
Patient population
The target population for this study was Chinese women over 60 years old without a history of fractures and whose bone mineral density (BMD) in the lumbar spine (L2-4) or femoral neck T value was less than or equal to À2.5 seconds (DEXA method), which is indicative of the necessity of drug intervention.
Treatments
Our model consisted of five strategies: fundamental supplement for bone health (daily oral administration of 600 mg of calcium and 125 IU vitamin D); once-weekly administration of 70 mg of alendronate; yearly intravenous administration of 5 mg of zoledronate; daily oral administration of raloxifene; and daily subcutaneous administration of 20 mg of teriparatide for 2 years. The ''drug holiday'' theory states that drugs are continued to be released from bone for months or years after the termination of treatment. Thus, we assumed a 2-year drug holiday after 5 and 3 years of alendronate and zoledronate treatments, respectively, as suggested by the 2017 Chinese guideline and 2016 American Association of Clinical Endocrinologists guideline. 3, 9 We also assumed that teriparatide was used for 2 years and stopped on the basis of medicine specifications.
We extracted data on the basis of the efficacy of these strategies from a recent network meta-analysis, including the risk of fracture after treatment in the target population. 10 Model parameters Transition probabilities Fracture rates. In this study, fracture incidence was defined in reference to the epidemiological study of Bow et al, 11 who quantified the incidence of clinical vertebral and hip fractures among postmenopausal women of different ages. The incidence of fractures in postmenopausal osteoporosis patients would be calculated by multiplying the incidence in the general population of postmenopausal women by the relative risk of fractures in patients with osteoporosis in different age groups compared with the general population of postmenopausal women. 4 The BMD values of different body parts of the patients will drastically increase after drug intervention. Hence, the risk rate of fracture in different body parts of patients who have received treatment will be drastically lower than those of patients who have not taken any treatment.
A meta-analysis by Murad et al involved 116 randomized controlled trials. In this meta-analysis, the odds ratio (OR) of the relative risk of hip and vertebral fractures in different antiosteoporosis drug groups versus the placebo group was calculated. 10 We converted the OR value to the relative risk (RR) in reference to a study by Zhang and Yu 12 by using the
, where Po represents the incidence of outcome measures in the control group. Our calculation reveals that RR obtained through calculation is consistent with OR because Po is low. Therefore, OR is used as RR, which is included in the model for calculation.
The formula for the risks of fractures in the model is as follows: (fracture risk of different age groups in the general population) Â (relative risk of fracture in patients with osteoporosis) Â (relative risk of fracture after drug intervention). In addition, the relative risks of refracture associated with the same location of the previous fracture increased. 13 Hence, the probability of second or subsequent fractures in the same location is multiplied by the relative risk of refracture in the same site 14 (Table 1) .
Mortality rates. In accordance with an epidemiological study involving the long-term follow-up surveys of 155,466 postmenopausal women in Taiwan reported by Chang et al, 15 we collected data on the mortality rates associated with fractures in different parts of the body at different ages. These fracture types included no fracture, hip fracture, vertebral fracture, and late hip fracture (Table 1 ).
Utilities
The current analysis considered the health outcomes on the basis of preferences. Life-year was adjusted to the healthrelated quality-of-life year by utility value. Utility values can range from 0 (death) to 1 (perfect health). QALYs can be calculated by multiplying life-year with utility value.
The health-related quality of life of women with osteoporosis, but without fracture history, is almost identical to that of the general population. 16 Hence, the health utility value of the ''no fracture'' state in this model used the health utility value of different age groups in the general population as calculated by Sun et al 17 by using the EuroQol five-dimensions questionnaire. Fractures reduce the health utility value of patients. We extracted the disutility value of the hip and clinical vertebral fractures of Asian populations from the study of Mori et al. 4 The disutilities of ''hip fractures'' and ''clinical vertebral fractures'' states were highest in the first year of fracture and reduced in the ''postfracture'' state, which lasts for the rest of the patient's life (Table 1) .
Cost
This research was conducted from the perspective of the Chinese health system. The costs involved mainly include the cost of medicine for the five treatment options, the cost of treatment for fractures at different locations, the monitoring fees for related drug treatments, BMD monitoring expenses, and zoledronate injection cost (Table 1) . We searched the provincial bid price of all drugs in 2018 through Yaozh (https://yaozh.com/), which is a big-data service platform for China's medical industry. We considered the median value as the reference prices of the drugs and calculated the annual drug cost of each strategy.
The cost of fractures in different body parts includes direct and indirect medical costs. Data were extracted from recent research on fracture burden in China. 18 Rehabilitation costs, auxiliary medical device costs, and hospital review fees accrued after discharge from a hospital with hip fractures are also generated each year. 3 the patient's creatinine clearance rate should be monitored when using alendronate for the first time. Serum calcium, phosphorus, magnesium, and creatinine levels, and renal function before each dose should be monitored when using zoledronate for the first time. Creatinine clearance and blood calcium levels during treatment should be monitored when using teriparatide for the first time. In China, bone mineral density (BMD) is measured annually during antiosteoporosis treatment. The costs of tests were obtained from the Fujian Provincial Price Bureau. 20 The costs were converted into US dollars (CYN 6.2527 ¼ US $12,018).
Sensitivity analyses
We performed univariate and probability sensitivity analyses. We used a wide range of drug costs, hospitalization costs, and utility, and varied the transition probability of each health state within 95% CIs. We performed second-order Monte Carlo probabilistic sensitivity analysis to estimate the total influence of the uncertainty of model parameters on the model. We used beta, gamma, and triangular and beta distribution to analyze probability, relative risk and cost, and utility parameters.
RESULTS
Base case analyses
Rollback analysis was conducted. Alendronate and raloxifene strategies were eliminated because they had lower utility and were more expensive than the other strategies. The zoledronate and calcium/vitamin D strategies were subjected to incremental cost-effectiveness analysis. The zoledronate strategy had an ICER of $7864.59/QALY. Thus, this strategy was more cost-effective relative to thresholds applied in China ($28,624/QALY). Then, incremental cost-effectiveness analysis was conducted on teriparatide and zoledronate strategies. The teriparatide strategy yielded an ICER of $470797.08/QALY. In contrast to that of the zoledronate strategy, the ICER of teriparatide strategy exceeded the threshold. Thus, this strategy was not cost-effective and was eliminated.
Sensitivity analyses
Sensitivity analyses show that the results were robust. The most sensitive parameter in the model was the relative risk of vertebral fracture of zoledronate (Fig. 2) . Model parameters were simulated by Monte Carlo 1,000 times in accordance with the distributions and value ranges shown in Table 2 .
The scatter plot comparing the zoledronate and calcium/ vitamin D strategies shows that most of the scatter localized below the dotted diagonal line, indicating that zoledronate had a high probability of being economical (Fig. 3A) . The scatter plot for the comparison of the teriparatide and zoledronate strategies shows that most of the scatter localized above the dotted diagonal line. This pattern indicates that teriparatide strategy had a very low probability of being economical within the acceptable threshold (Fig. 3B) . The cost-effectiveness acceptability curves show that zoledronate had 95% probability of being cost-effective at a willingness-to-pay threshold of $28,624/QALY (Fig. 4) .
Threshold analysis
Threshold analysis was performed by adjusting the range of teriparatide price. Teriparatide obtained an ICER of $28571.87/QALY, which is less than the threshold and demonstrates cost-effectiveness when the annual drug cost is $2620 (ie, the unit price of teriparatide is reduced from $935/2.4 to $218/2.4 mL). Vertebral fracture, beyond first year 0.868 0.827-0.922 Beta DISCUSSION We evaluated the cost-effectiveness of five different strategies for the treatment of osteoporosis in postmenopausal Chinese women. We identified the zoledronate strategy as the superior strategy on the basis of ICER. The base case analysis revealed that compared with the ICER of the calcium/vitamin D strategy, that of the zoledronate strategy was $7864.59/ QALY. This result indicates that the zoledronate strategy was cost-effective on the basis of the thresholds applied in China ($28,624/QALY). Although the teriparatide strategy had better therapeutic effect and offered better quality-of-life advantages than the zoledronate strategy, its ICER remarkably exceeded the threshold. The teriparatide strategy would be cost-effective only if its price was reduced by 76.7% (from $935/2.4 to $218/2.4 mL). Teriparatide was recommended for the prevention of fractures in people with previous fractures or at especially high risk of fractures in the 2016 American Association of Clinical Endocrinologists/American College of Endocrinology guidelines, given its better efficacy than other strategies. 9 Therefore, teriparatide may be a cost-effective antiosteoporosis strategy for people with a history of fractures or at especially high risk of fractures. However, no head-to-head study is available on the efficacy of teriparatide and other strategies in high-risk populations. Model   FIG. 2 . One-way sensitivity analysis. RR_Vertebral_fx_Zoledronate, relative risk of vertebral fracture of zoledronate; Cost_Zoledronate, annual cost of zoledronate at a dose of 5 mg/year intravenously; RR_Hip_fx_Zoledronate, relative risk of hip fracture of zoledronate; Mortality_rate_no_fx_80_89, mortality rate of ''no fracture'' status in 80 to 89-year-olds; Mortality_rate_no_fx_70_79, mortality rate of ''no fracture'' status in 70 to 79-year-olds; Utility_80_84, health utility value of the ''no fracture'' status in 80 to 84-year-olds; Utility_75_79, health utility value of the ''no fracture'' status in 75 to 79-year-olds; Utility_Post_Vertebral_fx, health utility value of the ''Vertebral fracture, beyond first year'' status; RR_same_location_Vertebral_fx, relative risks of subsequent fractures associated with prior fractures at the same vertebral location; Utility_70_74, health utility value of the ''no fracture'' status in 70-74 years old; Cost_post_hip_fx, post hospital discharge of hip fracture; Mortality_rate_no_fx_90, mortality rate of ''no fracture'' status in more than 90 years old; Utility_65_69, health utility value of the ''no fracture'' status in 65 to 69-year-olds; Cost_Vertebral_fx_H, hospitalization costs of vertebral fracture. parameters and results will need to be updated when relevant data become available. This study applied epidemiological data, costs, and utility values for the Chinese population. Hence, the results of the study could be applicable to postmenopausal women with osteoporosis in China. We applied the time-dependent Markov model in this study. Our model is consistent with reality and could be applied to simulate the long-term outcome of a patient's mortality from osteoporosis because the fracture risk rate, relative risk rate, and utility value of patients with osteoporosis change with age in the model.
Our study focuses on the most cost-effective medication plan for menopausal women who are older than or equal to 60 years and suffering from osteoporosis. The study population includes patients who suffer from osteoporosis but have never had a fracture. The study population in clinical trials included in the meta-analysis used in our study comprises patients who have osteoporosis, but have never had a fracture. 
FIG. 4.
Cost-effectiveness acceptability curves shows the probability of being cost-effective for competing strategies at different willingness-to-pay for quality-adjusted life-years (QALYs). If the initial treatment is administered when patients are 70 or 80 years old, fracture events may occur in 10 or 20 years without treatment. Afterwards, antiosteoporosis therapy is performed. Its effect cannot be compared with that of patients without fracture events at the same baseline. Therefore, 60 years is selected as the age of initial treatment without a cross-sectional comparison of the ages of different initial treatments.
COST-EFFECTIVENESS OF ANTIOSTEOPOROSIS
Our data and study design have several limitations. First, given that no head-to-head study on the five strategies for the treatment of osteoporosis in elderly postmenopausal women is available, the data on the effectiveness of the treatments used in this study were obtained from a recent network metaanalysis, which involved an indirect comparison of five competing strategies and placebos in reducing the incidence of fragility fractures in a population of patients with osteoporosis. The instructions on the use of teriparatide and raloxifene suggest that their effects on reducing the risk of hip fracture have not been confirmed. The network meta-analysis did not find statistically significant reductions in odds of hip fracture among women using teriparatide or raloxifene (teriparatide OR 0.42 [0.10; 1.82] and raloxifene OR 0.87 [0.63; 1.22]). Therefore, we conduct uncertainty analyses, which showed that the result of cost-effectiveness analysis is robust, and the overall result does not change because of the wide variation in this parameter. Second, our results may only apply to postmenopausal women in China and may not be applicable to women in other countries or to men. All cost parameters were set for China, which may be different from other countries. Meanwhile, the parameters ''relative risks of subsequent fractures associated with prior fractures at the same location'' and ''relative risk of fractures for individuals with osteoporosis,'' were obtained from foreign data given the absence of data relevant to the Chinese population. Third, our decisionanalytic model was a simplification of the actual disease outcome. Therapeutic strategies and clinical practice were based on Chinese guidelines and the recommendations of a clinical expert on metabolism. Our model did not reflect individual treatment decisions. Apart from this, because no relevant data about the Chinese population are available, only hip fracture and clinical vertebral fracture are set up, and no other osteoporotic fracture states, such as humerus and distal forearm fractures, are present. The effects of these states on treatment costs and quality of life are also disregarded. Fourth, only branded drugs were evaluated in this study because, in contrast to that of branded drugs, the quality of the Chinese generics of zoledronate, alendronate, teriparatide, and raloxifene cannot be determined. Finally, the persistence and adherence of patients to osteoporosis treatment affect the treatment and the risk of fracture. [21] [22] [23] Medication persistence and adherence parameters have been used in other studies. For example, Mori et al 4 performed univariate sensitivity analysis and showed that the results were sensitive to the RR value of nonpersistence of denosumab relative to alendronate. However, variations in the effect on ICER do not exceed the willingness of patients to pay for their treatment, that is, the conclusion remains unchanged. Mori et al 24 also considered the influence of medication persistence and adherence on the result. The univariate sensitivity analysis shows that the result is not sensitive to persistence and adherence parameters. The adherence and persistence were not considered in this study, and we assumed that patients would continue to receive standardized treatment as prescribed. The zoledronate strategy involves an intravenous infusion once a year and has a low frequency of administration and slightly adverse reactions. Thus, patient compliance for the zoledronate strategy is superior to that for the other four regimens. 25, 26 Hence, it can be speculated that the parameters of adherence and persistence would not change the conclusion that zoledronate is the most economical strategy.
CONCLUSION
From the perspective of the Chinese medical system, zoledronate is more cost effective than the calcium/vitamin D strategy, alendronate, raloxifene, and teriparatide for the treatment of osteoporosis in elderly postmenopausal women.
